Prager, Gerald W.

Trifluridine–tipiracil and bevacizumab in refractory metastatic colorectal cancer

Prager, G. W., Taieb, J., Fakih, M., Ciardiello, F., Van Cutsem, E., Elez, E., Cruz, F. M., Wyrwicz, L., Stroyakovskiy, D., Pápai, Z., et al. (2023) · New England Journal of Medicine

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 467

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Kornauth, C., Pemovska, T., Vladimer, G. I., Bayer, G., Bergmann, M., Eder, S., Eichner, R., Erl, M., Esterbauer, H., Exner, R., et al. (2022) · Cancer Discovery

Acute Myeloid Leukemia ResearchChronic Lymphocytic Leukemia Research

Cited by 206

Nesidioblastosis in adults: a challenging cause of organic hyperinsulinism.

Kaczirek, K., Soleiman, A., Schindl, M., Passler, C., Scheuba, C., Prager, G., Kaserer, K., & Niederle, B. (2003) · European Journal of Clinical Investigation

Neuroendocrine Tumor Research AdvancesPancreatic function and diabetes

Cited by 57

Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.

Tabernero, J., Prager, G. W., Fakih, M., Ciardiello, F., Van Cutsem, E., Elez, E., Cruz, F. M., Wyrwicz, L., Stroyakovskiy, D., Papai, Z., et al. (2023) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 46

Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: Post hoc analysis of the phase III SUNLIGHT trial

Tabernero, J., Taieb, J., Fakih, M., Prager, G. W., Van Cutsem, E., Ciardiello, F., Mayer, R. J., Amellal, N., Skanji, D., Calleja, E., et al. (2024) · ESMO Open

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 18